As separate companies, Biogen and Idec could not support their products and at the same time leverage the value of the associated large-molecule development infrastructure to create robust pipelines, balance risk, and thus help assure their future growth. By merging, they will be able to exploit their combined capabilities in large-molecule process development and manufacturing, which will give them both the means to reap the full rewards of organic growth and also the capability and capacity to partner with smaller companies in need of their kind of development expertise. While both companies face pipeline risk, Idec's Rituxan appears certain to continue to propel that firm's growth, justifying its higher P/E. Biogen's growth is slower and less certain. Should it further decline, it will be to the detriment of Idec's investors, who will have to wait at least 5-6 years to see the partnering model develop and the pipeline deepen.
By Mark L. Ratner
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.
Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.
Companies are exploring new mechanisms of action beyond traditional amyloid and tau and both investors and big pharma are willing to make deals when the science is compelling, panelists at Biotech Showcase said.
Licensing deals have been growing in popularity over outright acquisitions in the pharmaceutical industry over the past decade. Licensing deals have doubled in number from 2015 to 2024, while M&A activity has decreased post-COVID. We consider the advantages of licensing deals and review notable licensing deals from the past 10 years with the potential to deliver high value relative to their initial investment.
Crystal Qin has led LaNova Medicines’ swift rise in the biotech world through strategic partnerships and innovative R&D, highlighted by a record deal with big pharma.
In Vivo Rising Leader Amir Hefni, CEO of Resolution Therapeutics, discusses the company's advancements in macrophage cell therapies for inflammatory and fibrotic diseases, and his transition from big pharma to biotech leadership.
The sixth annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
